Synthetic process for fk-506 type macrolide intermediates
CA 2020072 A1 · Owner: Merck & Co. Inc. · Inventors: Askin, David; Joe, Daisy; Volante, Ralph P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
7478P/, 6/27/89:Fl, 17931, TITLE OF THE INVENTION NEW SYNTHETIC PROCESS FOR FK-506 TYPE, MACROLIDE INTERMEDIATES ABSTRACT OF THE DISCLOSURE, A process for the conversion of FR-506 (I,R = allyl;1) to FK-525 (XV) and analogous 23-membered ring macrolides differing in the C.1-N.7 segment of the molecule (e.g. XVI) and is also applicable to the analogs FK-523 (XVII) and FK-520 (XVIII). The overall process consists of three stages: (a) initial degradation of the primary macrolide to an acyclic fragment containing a selectively protected C.10-C.34 framework with a protected aldehyde function at C.10 and a free hydroxyl function at C.26, (b) reacylation of the C.26 hydroxyl function with an …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 28, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.